Sodium Carbonate → HCID 67620061、化合物
反応式
[NH:1]1[CH2:8][CH2:7][CH2:6][C@H:2]1[C:3]([OH:5])=O.[CH2:9]([NH:16][C:17](=[O:24])[C@H:18]([C@H:20]([CH2:22][CH3:23])[CH3:21])[NH2:19])[C:10]1[CH:15]=[CH:14][CH:13]=[CH:12][CH:11]=1.C(=O)([O-])[O-].[Na+].[Na+].Br[CH2:32][C:33]([C:35]1[CH:40]=[CH:39][CH:38]=[CH:37][C:36]=1[O:41][CH3:42])=[O:34]>C(#N)C>[CH3:42][O:41][C:36]1[CH:37]=[CH:38][CH:39]=[CH:40][C:35]=1[C:33](=[O:34])[CH2:32][N:1]1[CH2:8][CH2:7][CH2:6][C@H:2]1[C:3]([N:16]([CH2:9][C:10]1[CH:15]=[CH:14][CH:13]=[CH:12][CH:11]=1)[C:17](=[O:24])[C@H:18]([C@H:20]([CH2:22][CH3:23])[CH3:21])[NH2:19])=[O:5]参加物
5
実験手順
Using the procedure described in example 5, treatment of L-proline-L-isoleucine benzylamide (317 mg, 0.99 mmol), with sodium carbonate (211 mg, 1.99 mmol), and 2-bromo-2'-methoxyacetophenone (457 mg, 1.99 mmol, 2.0 eq) in acetonitrile (10 mL), provided 410 mg (88%) of L-isoleucine, N-[1-(2-(2-methoxyphenyl)-2-oxoethyl)-L-prolyl] benzylamide as a pale yellow oil.